CERO.OOTC
- CERo Therapeutics Holdings, Inc.
Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
-1.04/-4.84
|
|
Enterprise Value
1.90M
|
| Balance Sheet |
|
Book Value Per Share
-5.47
|
| Cash Flow |
|
Cash Flow Yield
--
|
| Income Statement |
|
Total Revenue
0
|
|
Operating Revenue Per Share
--
|
|
Industry Comparison
|
||||||||||||||||
|
||||||||||||||||
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables itto integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. |

0.11 
